INREAL – Nintedanib for changes in dyspnea and cough in chronic PF-ILD patients in everyday clinical practice: a real-world evaluation*

Background Nintedanib was shown to significantly slow the annual rate of decline in FVC in patients with chronic progressive fibrosing interstitial lung diseases (PF-ILD/PPF). The effects on the patient reported outcomes (PRO) dyspnea or cough have only been investigated scarcely, especially in a real-world cohort.